Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 112.210
- -0.030-0.03%
Close May 2 16:00 ET
- 112.210
- 0.0000.00%
Post 20:01 ET
5.47BMarket Cap-18.73P/E (TTM)
114.010High111.130Low700.76KVolume113.100Open112.240Pre Close78.67MTurnover1.91%Turnover RatioLossP/E (Static)48.77MShares139.13052wk High95.99P/B4.12BFloat Cap64.11052wk Low--Dividend TTM36.67MShs Float139.130Historical High--Div YieldTTM2.57%Amplitude1.940Historical Low112.257Avg Price1Lot Size
About Axsome Therapeutics Company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Company Profile
SymbolAXSM
Company NameAxsome Therapeutics
Listing DateNov 19, 2015
Issue Price9.00
Founded2012
CEODr. Herriot Tabuteau, M.D.
MarketNASDAQ
Employees683
Fiscal Year Ends12-31
AddressOne World Trade Center,22nd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10007
Phone1-212-332-3241
Websitehttp://www.axsome.com
Company Executives
- Name
- Position
- Salary
- Dr. Herriot Tabuteau, M.D.
- Chairman of the Board, President and Chief Executive Officer
- 10.36M
- Nick Pizzie
- Chief Financial Officer and Principal Accounting Officer
- 3.76M
- Mark Jacobson, M.A.
- Chief Operating Officer
- 4.25M
- Ari Maizel
- Chief Commercial Officer
- 3.20M
- Mark E. Saad
- Independent Director
- 408.59K
- Dr. Susan Mahony, M.B.A.,PhD
- Independent Director
- 398.31K
- Dr. Roger A. Jeffs, PhD
- Lead Independent Director
- 403.73K
- Dr. Mark Coleman, M.D.
- Independent Director
- 432.79K
- Hunter Murdock
- General Counsel
- 3.25M
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
